Is This the End of Curva?

2min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

There's various different types of newros bunce, and the one that is particularly interesting in this case is the development of what's called neutralizing antibodies. The fact that it was so much lower than what others had previously reported with the other m r a vacines as a major red flag. But when they looked at how many of these neutralizing antibodies, the antibodies that would actually block the virus from infecting your cell, looking at the curvac data, they were getting levels about the same as what people who had natural infections had - protection.

After a slew of wildly successful vaccine trials, this week marked a more underwhelming result. The third mRNA vaccine to complete phase three trials, developed by CureVac, is just 47% effective at staving off disease according to preliminary data. This is a stark contrast with previous mRNA vaccines from Moderna and Pfizer BioNtec which returned around twice that efficacy in their trials. In this episode of Coronapod, we ask why the CureVac vaccine has faltered, and what this might mean for the future of the pandemic and mRNA vaccine development.

News: CureVac COVID vaccine let-down spotlights mRNA design challenges

News Feature: How COVID unlocked the power of RNA vaccines

Subscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday.

Hosted on Acast. See acast.com/privacy for more information.